Clinical study in Parkinson's disease with two unique goals: 1) Proof-of-concept of CDNF protein for disease modification; 2) Validation of clinically tested device for intracerebral drug delivery

Project Information

TreatER

Grant agreement ID: 732386

DOI 10.3030/732386

Project closed

EC signature date 9 December 2016

Start date 1 January 2017

End date 31 December 2020

Funded under

• SOCIETAL CHALLENGES - Health, demographic change and well-being

Total cost € 8 705 549,75

EU contribution € 5 971 173,75

Coordinated by

HELSINGIN YLIOPISTO
Finland

• Novel drug delivered direct to brain may halt Parkinson's
  EN